Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Biodesix Inc (BDSX)

Biodesix Inc (BDSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Why Shares of CareDx Are Jumping Friday

The company's diagnostic tests may obtain better coverage from the Centers for Medicare & Medicaid Services.

BDSX : 1.7850 (+0.28%)
CDNA : 18.02 (-0.66%)
Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for first quarter ended March 31,...

BDSX : 1.7850 (+0.28%)
Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the fourth quarter and year ended...

BDSX : 1.7850 (+0.28%)
Biodesix to Participate at Cowen’s 43rd Annual Healthcare Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will participate...

BDSX : 1.7850 (+0.28%)
Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the fourth quarter and year ended...

BDSX : 1.7850 (+0.28%)
Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced positive coverage decisions from four private payers including Blue Cross...

BDSX : 1.7850 (+0.28%)
Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company’s Board...

BDSX : 1.7850 (+0.28%)
Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine

Biodesix, Inc . (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the Company was named the leading Proteomics Solutions Company in the...

BDSX : 1.7850 (+0.28%)
Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the closing of its underwritten public offering of 35,075,000 shares of...

BDSX : 1.7850 (+0.28%)
Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the pricing of an underwritten public offering of 30,500,000 shares of its...

BDSX : 1.7850 (+0.28%)

Barchart Exclusives

Buy This Precious Metal ETF to Benefit from Booming Hybrid Vehicle Sales
U.S. hybrid sales have risen at a torrid 35% year on year rate so far in 2024. According to S&P Global Mobility data cited by Reuters, hybrid sales are expected to more than triple over the next five years, and make up 24% of U.S. new car sales in 2028. That's great news for platinum demand - and this physical platinum ETF is the way to play this trend. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar